| Published Application/Species/Sample/Dilution | Reference |
|---|
- immunohistochemistry - paraffin section; mouse; 1:500; loading ...; fig 3c
| Drelon C, Berthon A, Sahut-Barnola I, Mathieu M, Dumontet T, Rodriguez S, et al. PKA inhibits WNT signalling in adrenal cortex zonation and prevents malignant tumour development. Nat Commun. 2016;7:12751 pubmed publisher |
- western blot; human; fig 1c
| Cao Q, Yamamoto J, Isobe T, Tateno S, Murase Y, Chen Y, et al. Characterization of the Human Transcription Elongation Factor Rtf1: Evidence for Nonoverlapping Functions of Rtf1 and the Paf1 Complex. Mol Cell Biol. 2015;35:3459-70 pubmed publisher |
| Zheng H, Xu X, Xing Y, Wei Z, Takahashi H, Masuda S, et al. Nuclear or cytoplasmic localization of Bag-1 distinctly correlates with pathologic behavior and outcome of gastric carcinomas. Hum Pathol. 2010;41:724-36 pubmed publisher |
| Porzionato A, Macchi V, Barzon L, Masi G, Iacobone M, Parenti A, et al. Immunohistochemical assessment of parafibromin in mouse and human tissues. J Anat. 2006;209:817-27 pubmed |
| Corbetta S, Vaira V, Guarnieri V, Scillitani A, Eller-Vainicher C, Ferrero S, et al. Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr Relat Cancer. 2010;17:135-46 pubmed publisher |
| Guarnieri V, Battista C, Muscarella L, Bisceglia M, de Martino D, Baorda F, et al. CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort. Cell Oncol (Dordr). 2012;35:411-22 pubmed publisher |
| Kim H, Oh Y, Kim S, Lee D, Kang H, Lee J, et al. Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma. Head Neck. 2012;34:201-6 pubmed publisher |
| Masi G, Barzon L, Iacobone M, Viel G, Porzionato A, Macchi V, et al. Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism. Endocr Relat Cancer. 2008;15:1115-26 pubmed publisher |
| De Mesquita Netto A, Gomez R, Diniz M, Fonseca-Silva T, Campos K, De Marco L, et al. Assessing the contribution of HRPT2 to the pathogenesis of jaw fibrous dysplasia, ossifying fibroma, and osteosarcoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115:359-67 pubmed publisher |
| Masi G, Iacobone M, Sinigaglia A, Mantelli B, Pennelli G, Castagliuolo I, et al. Characterization of a new CDC73 missense mutation that impairs Parafibromin expression and nucleolar localization. PLoS ONE. 2014;9:e97994 pubmed publisher |
| Cascon A, Huarte-Mendicoa C, Javier Leandro-García L, Leton R, Suela J, Santana A, et al. Detection of the first gross CDC73 germline deletion in an HPT-JT syndrome family. Genes Chromosomes Cancer. 2011;50:922-9 pubmed publisher |
| Cavaco B, Santos R, Felix A, Carvalho D, Lopes J, Domingues R, et al. Identification of de novo germline mutations in the HRPT2 gene in two apparently sporadic cases with challenging parathyroid tumor diagnoses. Endocr Pathol. 2011;22:44-52 pubmed publisher |
| Korpi-Hyovalti E, Cranston T, Ryhänen E, Arola J, Aittomaki K, Sane T, et al. CDC73 intragenic deletion in familial primary hyperparathyroidism associated with parathyroid carcinoma. J Clin Endocrinol Metab. 2014;99:3044-8 pubmed publisher |
| Zheng H, Takahashi H, Li X, Hara T, Masuda S, Guan Y, et al. Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas. Virchows Arch. 2008;452:147-55 pubmed |
| Fernandez-Ranvier G, Khanafshar E, Tacha D, Wong M, Kebebew E, Duh Q, et al. Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer. 2009;115:334-44 pubmed publisher |
| Sulaiman L, Nilsson I, Juhlin C, Haglund F, Höög A, Larsson C, et al. Genetic characterization of large parathyroid adenomas. Endocr Relat Cancer. 2012;19:389-407 pubmed publisher |
